Results 51 to 60 of about 70,021 (330)

Effects of Orotic Acid-Induced Non-Alcoholic Fatty Liver on the Pharmacokinetics of Metoprolol and its Metabolites in Rats

open access: yesJournal of Pharmacy & Pharmaceutical Sciences, 2019
Purpose: Preliminary study results have shown that rats with non-alcoholic fatty liver disease (NAFLD) induced by 1% orotic acid-containing diet have decreased hepatic CYP2D activity.
Won Seok Bang   +4 more
doaj   +1 more source

Prophylactic use of carvedilol to prevent ventricular dysfunction in patients with cancer treated with doxorubicin [PDF]

open access: yes, 2018
Objective: Deterioration in ventricular function is often observed in patients treated with anthracyclines for cancer. There is a paucity of evidence on interventions that might provide cardio-protection.
Abrar, Mohammed Burhan   +8 more
core   +1 more source

In-line NIR spectroscopy for the understanding of polymer-drug interaction during pharmaceutical hot-melt extrusion [PDF]

open access: yes, 2012
The aim was to evaluate near-infrared spectroscopy for the in-line determination of the drug concentration, the polymer-drug solid-state behaviour and molecular interactions during hot-melt extrusion.
Adriaensens, Peter   +7 more
core   +2 more sources

The effect of metoprolol on plasma lipids [PDF]

open access: yesPostgraduate Medical Journal, 1979
Summary Fifteen hypertensive patients entered a single-blind study to examine the effects of metoprolol (100 mg twice daily) on fasting plasma lipids. In 12 patients who completed the study, non-esterified fatty acid concentrations fell, but cholesterol and triglyceride levels were unchanged after 12 weeks' treatment.
R. M. Pearson   +3 more
openaire   +3 more sources

Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF) [PDF]

open access: yes, 2014
Aim<p></p> To describe the baseline characteristics and treatment of the patients randomized in the PARADIGM-HF (Prospective comparison of ARNi with ACEi to Determine Impact on Global Mortality and morbidity in Heart Failure) trial, testing ...
Adel R. Rizkala   +11 more
core   +2 more sources

Once-daily metoprolol for hypertension [PDF]

open access: yesPostgraduate Medical Journal, 1981
Summary In a randomized cross-over trial the antihypertensive effect of metoprolol given once daily was compared with its effects after twice-daily dosage. Metoprolol given as a single morning dose had a useful antihypertensive effect for 24 hr and may be given in this way for the treatment of hypertension.
D. C. Banks, M. J. Ward, J. M. Roland
openaire   +3 more sources

The Anti-Inflammatory Effect of the β1-Adrenergic Receptor Antagonist Metoprolol on High Glucose Treated Human Microvascular Retinal Endothelial Cells

open access: yesCells, 2021
Hyperglycemia-induced impairment of the blood-retinal barrier represents the main pathological event in diabetic retinopathy that is elicited by a reduced cellular response to an accumulation of reactive oxygen species (ROS) and increased inflammation ...
Giovanni Giurdanella   +9 more
doaj   +1 more source

Carvedilol and metoprolol are both able to preserve myocardial function in type 2 diabetes

open access: yesPhysiological Reports, 2020
Purpose Increasing cohorts of patients present with diabetic cardiomyopathy, and with no targeted options, treatment often rely on generic pharmaceuticals such as β‐blockers. β‐blocker efficacy is heterogenous, with second generation β‐blocker metoprolol
Carol T. Bussey   +6 more
doaj   +1 more source

Long‐Term Mortality Associated With Use of Carvedilol Versus Metoprolol in Heart Failure Patients With and Without Type 2 Diabetes: A Danish Nationwide Cohort Study

open access: yesJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Background Carvedilol may have favorable glycemic properties compared with metoprolol, but it is unknown if carvedilol has mortality benefit over metoprolol in patients with type 2 diabetes (T2D) and heart failure with reduced ejection fraction (HFrEF ...
Brian Schwartz   +8 more
doaj   +1 more source

Novel Electroactive Therapeutic Platforms for Cardiac Arrhythmia Management

open access: yesAdvanced Science, EarlyView.
Electroactive platforms offer promising applications in cardiac arrhythmia. Based on their energy sources and mechanisms, electroactive platforms are categorized into i) direct electrical stimulation, ii) self‐powered electroactive systems, iii) physical stimuli‐mediated electroactive systems, and iv) conductive systems, and their applications in ...
Juwei Yang   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy